2020
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Cawley J, Wright Z, Meleo K, Post G, Clifford C, Vickery K, Vail D, Bergman P, Thamm D. Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal Of Veterinary Internal Medicine 2020, 34: 882-889. PMID: 32064697, PMCID: PMC7096650, DOI: 10.1111/jvim.15723.Peer-Reviewed Original ResearchConceptsMedian progression-free survival timeOverall response rateComplete responseMulticentric lymphomaAdverse eventsL-asparaginaseProspective single-arm clinical trialProgression-free survival timeSingle-arm clinical trialNegative prognostic factorRelapse of lymphomaTreatment of lymphomaNovel antineoplastic agentPrognostic factorsChemotherapy protocolsClinical trialsRabacfosadineSurvival timeIU/Response rateClinical importanceLymphomaMultivariate analysisAntineoplastic agentsConcurrent use
2009
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP‐MA) for the treatment of canine lymphoma
Daters A, Mauldin G, Mauldin G, Brodsky E, Post G. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP‐MA) for the treatment of canine lymphoma. Veterinary And Comparative Oncology 2009, 8: 11-22. PMID: 20230577, DOI: 10.1111/j.1476-5829.2009.00199.x.Peer-Reviewed Original ResearchConceptsMultidrug chemotherapy protocolMulticentric lymphomaMedian survivalChemotherapy protocolsSurvival timeOverall median survivalDose of doxorubicinCanine multicentric lymphomaMitoxantrone dosesOverall remissionSteroid administrationMedian remissionHistorical controlsRemission timeCanine lymphomaLymphomaRemissionMitoxantroneDogsFurther studiesL-asparaginaseSurvivalDoxorubicinDaysHypercalcaemia